40. Anticoagulants Flashcards
mechanisms involved in hemostasis
- vasoconstriction
- formation of platelet plug
- sequential activation of clotting factors
- reparation of the opening in the damaged vessel by growth of fibrous tissue
How does the coagulation cascade lead to formation of fibrin clot
- injured cells release prothrombin activator
- prothrombin activator changes prothrombin to thrombin
- thrombin changes fibrinogen to fibrin
- fibrin forms insoluble web over injured area to stop blood flow
atherosclerosis often involves arteries supplying what areas of the body
- heart -> MI
- brain -> stroke
- legs -> DVT
3 types of antithrombotic medications
- anticoagulants (prevents new clot formation -> does not dissolve formed clots)
- antiplatelets (prevent arterial thrombosis)
- thrombolytics (dissolve thrombi and limit tissue damage)
indication for use of anticoagulants
- thrombophlebitis
- DVT
- PE
- ACS -> PCI or STEMI
MOA of heparin
- varies according to dosage
- low dose: inactivates factor Xa and inhibits conversion of prothrombin to thrombin
- high dose: inactivates IX, X, XI, XII, and thrombin and inhibiting conversion of fibrinogen to fibrin
side effects/adverse effects of heparin
- HIT
- ecchymosis
- bleeding risk
- hypersensitivity
- N/V
How do you evaluate effectiveness of heparin
PTT in therapeutic range (based on institution); around 60-90
contraindications of heparin
severe thrombocytopenia
patient teaching for heparin
- rotate injection sites (to be given SQ)
- increased bleeding risk (hold pressure to wounds and report severe sxs)
What type of medicine is enoxaparin
LMWH
MOA of enoxaparin
inactivates coagulation factor Xa and produces anticoagulation
uses of enoxaparin
- DVT prophylaxis
- ACS
- unstable angina
- acute DVT
administration of enoxaparin
- peaks 3-5 hours and lasts 12 hours
- subcutaneous injection
- air bubble needed to follow the injection
- don’t rub site after injection
adverse effects of enoxapain
- injection site hematoma
- nausea
- peripheral edema
- bleeding
safety info for enoxaparin
- lower bleeding risk than heparin
- more stable response
- no PTT monitoring
antidote to heparin and enoxaparin
protamine sulfate
antibodies develop to platelet factor 4 complexed w/ heparin; may also develop w/ LMWH but less common
heparin induced thrombocytopenia (HIT
sxs of HIT
- thrombocytopenia
- thrombosis by peripheral platelet consumption and platelet activation
- platelets decrease by 30-50% of baseline
MOA of warfarin
interferes w/ hepatic synthesis of vitamin K dependent clotting factors
uses of warfarin
- prevention of venous thromboembolism
- atrial fibrillation
- embolization
- coronary thrombosis
- pulmonary embolism
- inherited clotting disorders